Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Bergsland

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Current Treatment Options in Oncology|August 19, 2005
Anti-angiogenic strategies in gastrointestinal malignanciesJonathan Whisenant, Emily Bergsland
The Oncologist|June 5, 2004
Maximizing the potential of bevacizumab in cancer treatmentEmily Bergsland, Maura N Dickler
Cancers|July 29, 2023
Grade Progression and Intrapatient Tumor Heterogeneity as Potential Contributors to Resistance in Gastroenteropancreatic Neuroendocrine TumorsDiana Grace Varghese, Jaydira Del Rivero, Emily Bergsland
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlapDavid S Klimstra, Himisha Beltran, Rogerio Lilenbaum, et al.
The Oncologist|October 30, 2024
Metastatic insulinoma-outcomes in the current eraUmesh Masharani, Sheila Lindsay, Farhana Moon, et al.
The Journal of Clinical Investigation|May 3, 2003
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitorsGabriele Bergers, Steven Song, Nicole Meyer-Morse, et al.
Cancer Metastasis Reviews|June 14, 2006
Targeting growth factors and angiogenesis; using small molecules in malignancyHarold J Wanebo, Athanassios Argiris, Emily Bergsland, et al.
Cell Reports|April 21, 2015
Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapyLee B Rivera, David Meyronet, Valérie Hervieu, et al.
Clinical Colorectal Cancer|February 19, 2008
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinomaJordan D Berlin, Alan Venook, Emily Bergsland, et al.
Medical Oncology (Northwood, London, England)|April 11, 2017
Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practicesMaurice Herring, Lynn Huynh, Mei Sheng Duh, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Current Treatment Options in Oncology|August 19, 2005
Anti-angiogenic strategies in gastrointestinal malignanciesJonathan Whisenant, Emily Bergsland
The Oncologist|June 5, 2004
Maximizing the potential of bevacizumab in cancer treatmentEmily Bergsland, Maura N Dickler
Cancers|July 29, 2023
Grade Progression and Intrapatient Tumor Heterogeneity as Potential Contributors to Resistance in Gastroenteropancreatic Neuroendocrine TumorsDiana Grace Varghese, Jaydira Del Rivero, Emily Bergsland
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlapDavid S Klimstra, Himisha Beltran, Rogerio Lilenbaum, et al.
The Oncologist|October 30, 2024
Metastatic insulinoma-outcomes in the current eraUmesh Masharani, Sheila Lindsay, Farhana Moon, et al.
The Journal of Clinical Investigation|May 3, 2003
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitorsGabriele Bergers, Steven Song, Nicole Meyer-Morse, et al.
Cancer Metastasis Reviews|June 14, 2006
Targeting growth factors and angiogenesis; using small molecules in malignancyHarold J Wanebo, Athanassios Argiris, Emily Bergsland, et al.
Cell Reports|April 21, 2015
Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapyLee B Rivera, David Meyronet, Valérie Hervieu, et al.
Clinical Colorectal Cancer|February 19, 2008
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinomaJordan D Berlin, Alan Venook, Emily Bergsland, et al.
Medical Oncology (Northwood, London, England)|April 11, 2017
Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practicesMaurice Herring, Lynn Huynh, Mei Sheng Duh, et al.
Pageof 7